Allergan (AGN) Offering Possible 17.37% Return Over the Next 3 Calendar Days

Allergan's most recent trend suggests a bullish bias. One trading opportunity on Allergan is a Bull Put Spread using a strike $227.50 short put and a strike $222.50 long put offers a potential 17.37% return on risk over the next 3 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $227.50 by expiration. The full premium credit of $0.74 would be kept by the premium seller. The risk of $4.26 would be incurred if the stock dropped below the $222.50 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Allergan is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Allergan is bullish.

The RSI indicator is above 80 which suggests that the stock is in overbought territory.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Allergan

New migraine drugs have promise — and a $8,500 price tag
Fri, 09 Jun 2017 16:02:31 +0000
They’re the first drugs developed for migraine in a long time. But migraine patients worry they won’t be able to access them.

Valeant Pharmaceuticals: Bigger is Better
Thu, 08 Jun 2017 16:54:00 +0000
Valeant Pharmaceuticals International (VRX) has sold its iNova division for $930 million. Valeant plans to throw the cash from the sale at its debt load, bringing the company within $500 million of it goal of $5 billion in debt reduction by February 2018. Gary Nacham at BMO Capital Markets was pleased to see Valeant “finally execute” on the deal and applauded the company’s aggressive debt reduction strategy.” Still, he notes the sale “does not move the needle on VRX’s net leverage, which remains at a very high 7.8x,” so assets sales “will need to continue and at some point will probably need to be of a much greater magnitude.” Meanwhile, he notes that the deal highlights some challenges for Valeant in executing these asset sales.

Allergan to Buy Keller Funnel, Boost Plastic Surgery Unit
Thu, 08 Jun 2017 14:05:02 +0000
Allergan plc (AGN) announced a deal to acquire privately held medical device company Keller Medical, Inc, which makes Keller Funnel, for an undisclosed amount.

Alkermes Gets FDA Nod for Two Month Dose of Aristada
Wed, 07 Jun 2017 14:54:02 +0000
Alkermes plc (ALKS) announced that the FDA has approved two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.

Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab
Wed, 07 Jun 2017 13:00:00 +0000
THOUSAND OAKS, Calif., June 7, 2017 /PRNewswire/ — Amgen (AMGN) and Allergan plc. (AGN) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the Biologics License Application (BLA) for ABP 215, a biosimilar candidate to Avastin® (bevacizumab), on July 13, 2017. “Amgen has a long and proud heritage in oncology, and we are committed to providing physicians and patients a range of high quality therapeutic options,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. The Committee will review analytical, pharmacokinetic and clinical data from studies involving ABP 215, including results from a Phase 3 study in patients with non-squamous non-small cell lung cancer (NSCLC).

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.